Dr. Reddy's Allots 12,665 Equity Shares Under ESOP Schemes
Dr. Reddy's Laboratories allotted 12,665 equity shares on February 17, 2026, under its ESOP schemes. These shares were exercised at various prices including Re.1/-, Rs. 735.80/-, and Rs. 521.40/-. Post-allotment, the company's total issued shares are 83,46,44,020.
The allotment of a relatively small number of shares under ESOPs is a standard corporate practice and is unlikely to have a material impact on the company's overall valuation or stock performance.
The announcement is a routine disclosure regarding the allotment of shares under employee stock option schemes, which does not inherently impact the company's financial performance or market position significantly.
Dr. Reddy's Laboratories Limited announced the allotment of 12,665 equity shares of Re.1/- each, fully paid up, on February 17, 2026. This allotment was made to eligible employees who exercised their Stock Options under the Dr. Reddy’s Employees Stock Options Scheme, 2002, and the Dr. Reddy’s Employees ADR Stock Options Scheme, 2007.
The shares were issued pursuant to the exercise of stock options. A portion of these shares, specifically 5,115, were exercised at Re.1/- per share with no premium. Another 1,300 shares were exercised at Rs. 735.80/- per share with a premium of Rs. 734.80/-, and the remaining 6,250 shares were exercised at Rs. 521.40/- per share with a premium of Rs. 520.40/-.
Following this allotment, the total issued shares of the company have increased to 83,46,44,020. The total issued share capital now stands at Rs. 83,46,44,020. The newly allotted shares rank pari passu with the existing shares.
What to do with a filing like this
Dr. Reddy's Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under designated person disclosures. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Dr. Reddy's Laboratories Limited. Read the original for the full detail.